USFDA conducted an inspection at Zydus Lifesciences Limited's manufacturing facility SEZ-1 at Pharmez, Ahmedabad from March 20 to March 24, 2023, the company announced through an exchange filing. The inspection was a pre-approval inspection (PAI) and a GMP Audit that concluded with three observations.
The company said that there were no data integrity related observations and the company is addressing these observations.
Zydus received final approval from USFDA for Lubiprostone Capsules, the company announced on March 24.
Zydus Lifesciences shares
Allahabad High Court Grants Interim Relief To Cricketer Yash Dayal In Sexual Harassment Case
Ganeshotsav 2025: Lalbaugcha Raja Mandal Asked To Disclose Safety Clearances For 50-Foot Pandal
Panvel Municipal Corporation Declares Holiday For All Schools And Colleges On July 15 Amid IMD Red Alert For Heavy Rainfall
Uttarakhand Tragedy: 8 Dead, 6 Injured After Vehicle Plunges Into 150-Meter Deep Gorge In Pithoragarh; PM Modi Announces Ex-gratia Of ₹2 lakh
The shares of Zydus Lifesciences on Friday closed at Rs 480.05, down by 0.47 per cent.
